Cancer drug tested in fight against Alzheimer's
NCT ID NCT04070378
Summary
This small, early-stage study explored whether a drug called daratumumab, which is approved for a type of blood cancer, could help people with mild to moderate Alzheimer's disease. The drug targets a specific protein on immune cells that may contribute to brain inflammation in Alzheimer's. Researchers gave the drug to 16 participants to see if it could lead to meaningful improvements in memory and thinking tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Litwin-Zucker Research Center
Manhasset, New York, 11030, United States
Conditions
Explore the condition pages connected to this study.